🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to scientists.

An International Public Health Issue

The sexually transmitted infection are increasing globally, with data suggesting over 82 million new cases each year. Notably increased rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the reality of rising global incidence, increasing antimicrobial resistance and the very limited available drugs currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, also known as a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This drug, which is additionally indicated for urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a innovative non-profit model for medication research. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Results and Worldwide Availability

As per data released by a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which involves an injection and a pill. The study involved nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have expressed optimism. Access to a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for public health efforts. This is considered essential to lessen the impact of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.